
Opinion|Videos|March 6, 2025
Key Considerations for Oncology Pharmacists When Selecting and Sequencing ADC Therapies
Panelists discuss how when making antibody-drug conjugate (ADC) treatment decisions for patients with metastatic breast cancer (mBC), pharmacists primarily consider patient-specific factors such as biomarker status, prior therapies, disease burden, and comorbidities. ADCs are typically introduced after standard first-line treatments show inadequacy or in specific molecular subtypes that demonstrate strong responses to targeted therapy.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- What key factors guide pharmacists in treatment sequencing decisions when multiple ADCs are available for mBC, and when is ADC therapy typically introduced?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
2
Celebrating the Pharmacist’s Impact: How Pharmacists Elevate Care in Every Setting
3
FDA Approves 1-Minute HIV Self-Test
4
How Pharmacists Can Navigate Legal Complexities With Most Favored Nation Status
5